---
title: "XORTX Therapeutics Inc. (XRTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/XRTX.US.md"
symbol: "XRTX.US"
name: "XORTX Therapeutics Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T22:44:17.658Z"
locales:
  - [en](https://longbridge.com/en/quote/XRTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/XRTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/XRTX.US.md)
---

# XORTX Therapeutics Inc. (XRTX.US)

## Company Overview

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.xortx.com](https://www.xortx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.31 | 117 | - | - | - |
| PB | 2.82 | 106 | 2.06 | 1.61 | 1.34 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-09-18T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.32 |
| Highest Target | 70.15 |
| Lowest Target | 70.15 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/XRTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/XRTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/XRTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/XRTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**